Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 3Withdrawn 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 11Lymphoid 3Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia, Biphenotypic, Acute 3Leukemia 2

Interventions

Cyclophosphamide 170Rituximab 143Specimen Handling 82venetoclax 79fludarabine 78Vincristine 69obinutuzumab 67Doxorubicin 66Prednisone 65Biopsy 64Magnetic Resonance Spectroscopy 62zanubrutinib 52Lenalidomide 52Dexamethasone 49Methotrexate 43Cytarabine 43blinatumomab 40acalabrutinib 37Immunotherapy, Adoptive 37Bendamustine Hydrochloride 37Etoposide 32fludarabine phosphate 31ibrutinib 28glofitamab 28polatuzumab vedotin 26pirtobrutinib 24orelabrutinib 24Gemcitabine 23Injections 21Mercaptopurine 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × revumenib × Lymphoid × Clear all
NCT04065399 2026-03-18

AUGMENT-101

Syndax Pharmaceuticals

Phase 1/2 Recruiting
447 enrolled 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06575296 2026-03-05

Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

City of Hope Medical Center

Phase 1 Recruiting
27 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07356154 2026-01-21

A Study of Revumenib and Mezigdomide in People With Leukemia

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
52 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡